American Society of Hematology Annual Meeting
Medicare Part D Low-Income Subsidies Increase Access to Multiple Myeloma Treatment
Treatment and outcomes for multiple myeloma (MM) have been greatly improved by the introduction of parenteral chemotherapy and novel oral agents such as lenalidomide and thalidomide. However, the cost of those agents typically exceeds $5,000 per month, which continues hinder their accessibility, according to Adam J. Olszewski, MD, in the Division of Hematology-Oncology at Alpert Medical School at Brown University, in Providence, RI. He discussed the ongoing financial difficulties for patients, insurers, and healthcare systems on Monday, December 5, at the 58th American Society of Hematology Annual Meeting and Exposition in San Diego, CA.
December 08, 2016